Navigation Links
Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

d of 2007. The Company has a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for its Phase 3 trial, and has also received Fast Track designation for FavId from the FDA.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, manufacturing and marketing FavId or Favrille's other product candidates; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates and the timing of any such approvals; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId re
'"/>




Page: 1 2 3

Related medicine technology :

1. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/1/2015)... 24, 2015 Research ... of the "2015 Strategies in the Home/Self ... This new 175-page report provides analysis of ... (strips and meters), pregnancy, ovulation, and occult blood. ... requirements, technologies, and competitive profiles. The ...
(Date:7/1/2015)... , July 1, 2015  Unilife Corporation (NASDAQ: ... supplier of injectable drug delivery systems, announced today that ... of June 30, 2015. This amendment removed a covenant ... in cash receipts from customers during the six months ... to any of the terms of the debt agreement ...
(Date:7/1/2015)... , July 1, 2015  MEI Pharma, Inc. (Nasdaq: ... of novel therapies for cancer, announced today that Daniel ... present at the inaugural Cantor Fitzgerald Healthcare Conference on Wednesday, ... Le Parker Meridien in New York ... at www.meipharma.com . A replay will be available approximately ...
Breaking Medicine Technology:2015 Strategies in the Home/Self Testing Market 2Unilife and OrbiMed Amend Debt Financing Agreement 2Unilife and OrbiMed Amend Debt Financing Agreement 3MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference 2
... Simulated Environment Concepts (SMEV.PK), the manufacturer and developer of ... that the Company has entered into what they believe may ... expects that much of the difficult items in prepping the ... much more knowledgeable today about the auditing process than they ...
... Inc., a medical device company that manufactures the world,s first ... teeth, today announced that it has received an additional FDA ... for Conductive hearing loss is the second for the SoundBite ... "We are pleased that the uses of ...
Cached Medicine Technology:Simulated Environment Concepts Nears Audit Completion 2Simulated Environment Concepts Nears Audit Completion 3Sonitus Medical Receives Second FDA Clearance for SoundBite™ Hearing System 2
(Date:7/1/2015)... ... 2015 , ... With all final regulatory approvals in place ... N.Y., is now a member of national system Trinity Health, effective immediately. ... committed to delivering high-value care, said Richard J. Gilfillan, M.D., president and CEO, ...
(Date:7/1/2015)... ... July 01, 2015 , ... For decades, researchers in the genetics field have ... the brain, never changing after development in the womb. Now, researchers from the Icahn ... brain cells throughout life – a process which helps to switch genes on and ...
(Date:7/1/2015)... ORANGE, Calif. (PRWEB) , ... July 01, 2015 ... ... advanced orthodontic technology and services, today announced that its fifth annual Smile for ... has raised $80,000 for the non-profit organization. In addition to supporting S4L in ...
(Date:7/1/2015)... ... 01, 2015 , ... The Collaborative for Children and Families (CCF) announced that ... will allow CCF to improve quality of care and save costs for the child ... to many changes in New York’s Medicaid system. Experts agree that children need thorough ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... training leaders Lora Posey (Manager, National Sales Training and Development) and Chuck Corso ... Network (LTEN) Conference in Phoenix, AZ. LTEN brings together learning and development professionals ...
Breaking Medicine News(10 mins):Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4
... , , LOS ANGELES, Sept. 14 ... it has launched CAP Cares, a program created to help its ... adverse patient outcome. , , CAP is encouraging ... after an incident that is either a known risk of medical ...
... UCLA School of Dentistry consistently ranks among the country,s top ... past three fiscal years, the school has secured nearly $30 ... Now, the dental school has received a major infusion of ... for Oral/Head & Neck Oncology Research. ...
... a previously unknown substance in spinal fluid that can ... in a thesis from the Sahlgrenska Academy at the ... research on new medications., The substance is a beta-amyloid ... studies that Alzheimer,s patients have higher levels of the ...
... , , SAN FRANCISCO, Sept. 14 ... Russo as Vice President of Blue Shield of California,s Individual, Small ... for strategy, business planning, growth, and overall results for the ISGBU ... development of new products for seniors. Russo will be based ...
... , , CAMBRIDGE, Mass., ... David Ebersman has joined the Company,s Board of Directors. ... He served at Genentech from 1994-2009 in a number ... financial officer, senior vice president of product operations, vice ...
... ... Kimball celebrate Brian Harris,s story and continue to crusade for adequate support for all people ... Pompano ... as the winner of the GlucoStories & Charlie Kimball Share Your Story Contest. Brian ...
Cached Medicine News:Health News:Cooperative of American Physicians, Inc. Launches CAP Cares 2Health News:UCLA School of Dentistry to build new cancer research facility 2Health News:UCLA School of Dentistry to build new cancer research facility 3Health News:Marc Russo Named Vice President of Individual, Small Group, and Government Business Unit at Blue Shield of California 2Health News:David Ebersman Joins Ironwood Board of Directors 2Health News:Winner Announced in GlucoStories Contest 2Health News:Winner Announced in GlucoStories Contest 3Health News:Winner Announced in GlucoStories Contest 4
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide smooth handle with polished finish....
Ergotec Vetriretinal Instrument System. Fine angled tips (3 mm). 20 gauge shaft length with black tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge....
Ergotec Vetriretinal Instrument System. Ultra-fine 2.8 mm jaws. Angled 55 degrees. 20 gauge shaft. 25 mm in length with black tip. Overall length from rear rotation knob to tip....
Medicine Products: